Grant: Master's Award: Canada Graduate Scholarships
McMaster University
$17,500.00
Developing an Off the Shelf TAC-T Cell Therapy using Covalent Immune Reprogramming Molecules
FY 2020-21
Summary
Immunotherapy is the use of the immune system to target and fight disease. In the field of cancer research, the immune system has proven to be an extremely effective tool. Adoptive T cell transfer (ATCT) uses immune cells (T-cells) taken out of a patient and engineered to target and kill cancer cells. These have proven to be effective with two clinically approved treatments, however, there still exists production difficulty, time, and cost issues associated with these therapies. T-cell antigen coupler (TAC) receptor T-cells are a new advancement in the field and are engineered to target cancer cells, killing them using the natural signalling pathway of the immune cell. In this project we plan to overcome the current time and accessibility issues faced by ATCT therapies by developing TAC T-cells targeted toward small covalent immune reprogramming molecules (CIR's). These CIR's will be used to permanently link the T-Cells with a molecule that can guide them to cancer cells. The advantage of using these CIR's is that they can be easily made and modified to create a library of molecules that can target different cancer types. The goal of this project is to create a universal T-cell therapy where one set of T-cells can be manufactured and modified using the library of CIR's to go after various different types of cancer. This combination of technologies is hypothesized to overcome some of the largest current limitations in the field as it removes the need to re-engineer cells for each new target and person, in turn lowering both production time and cost. This would bring to the field a new accessible treatment option that can be tailored easily for each patient.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
449759
Name
Serniuck Nickolas
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Developing an Off the Shelf TAC-T Cell Therapy using Covalent Immune Reprogramming Molecules
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer Immunotherapy; Cell Biology; Chemical Biology; Chemical Immunology; Engineered T-Cells; Molecular Biology; Organic Synthesis
Abstract
Immunotherapy is the use of the immune system to target and fight disease. In the field of cancer research, the immune system has proven to be an extremely effective tool. Adoptive T cell transfer (ATCT) uses immune cells (T-cells) taken out of a patient and engineered to target and kill cancer cells. These have proven to be effective with two clinically approved treatments, however, there still exists production difficulty, time, and cost issues associated with these therapies. T-cell antigen coupler (TAC) receptor T-cells are a new advancement in the field and are engineered to target cancer cells, killing them using the natural signalling pathway of the immune cell. In this project we plan to overcome the current time and accessibility issues faced by ATCT therapies by developing TAC T-cells targeted toward small covalent immune reprogramming molecules (CIR's). These CIR's will be used to permanently link the T-Cells with a molecule that can guide them to cancer cells. The advantage of using these CIR's is that they can be easily made and modified to create a library of molecules that can target different cancer types. The goal of this project is to create a universal T-cell therapy where one set of T-cells can be manufactured and modified using the library of CIR's to go after various different types of cancer. This combination of technologies is hypothesized to overcome some of the largest current limitations in the field as it removes the need to re-engineer cells for each new target and person, in turn lowering both production time and cost. This would bring to the field a new accessible treatment option that can be tailored easily for each patient.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Serniuck, Nickolas
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~